Retinitis Pigmentosa Market

pharma-news-for-bayer-klotho-trethera

Jul 15, 2025

Nanoscope’s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer’s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences’ KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera’s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx’s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer

top-8-gene-therapies-for-retinitis-pigmentosa-treatment

Jul 26, 2024

Top 8 Breakthrough Gene Therapies for Retinitis Pigmentosa Treatment

Retinitis pigmentosa

Mar 27, 2020

What is driving Retinitis pigmentosa market forward?

Retinitis Pigmentosa

Mar 23, 2020

Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper